Born out of Omega push for pandemic treatments, Aerium Therapeutics enters long Covid R&D

Aeri­um Ther­a­peu­tics, which Omega Funds seed­ed in 2021 and un­veiled in spring 2022 to take on Covid-19 with new mon­o­clon­al an­ti­bod­ies, will at­tempt to treat long Covid with a Phase II tri­al set to start lat­er this month.

The move comes as the Na­tion­al In­sti­tutes of Health kicks off a slate of stud­ies test­ing po­ten­tial treat­ments and med­ical de­vices for long Covid, a lin­ger­ing con­di­tion of the pan­dem­ic that most bio­phar­mas have avoid­ed. It al­so comes as Ax­cel­la Ther­a­peu­tics said Thurs­day it con­tin­ues search­ing for al­ter­na­tives to take for­ward its long Covid treat­ment can­di­date, which failed a Phase II last year but got clear­ance from FDA for ad­di­tion­al test­ing in a Phase IIb/III tri­al.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters